Modality
Radioligand
MOA
PD-1i
Target
C5
Pathway
Proteasome
MCCIgANFL
Development Pipeline
Preclinical
~Feb 2011
→ ~May 2012
Phase 1
~Aug 2012
→ ~Nov 2013
Phase 2
~Feb 2014
→ ~May 2015
Phase 3
~Aug 2015
→ ~Nov 2016
NDA/BLA
~Feb 2017
→ ~May 2018
Approved
Aug 2018
→ Sep 2031
ApprovedCurrent
NCT03048338
1,631 pts·IgAN
2020-02→2030-08·Not yet recruiting
NCT07371961
2,467 pts·IgAN
2018-08→2031-09·Not yet recruiting
NCT04775382
2,866 pts·MCC
2024-06→2030-10·Terminated
6,964 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2030-08-014.3y awayPh3 Readout· IgAN
2030-10-144.5y awayPh3 Readout· MCC
2031-09-265.5y awayPh3 Readout· IgAN
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Not yet…
Approved
Not yet…
Approved
Termina…
Catalysts
Ph3 Readout
2030-08-01 · 4.3y away
IgAN
Ph3 Readout
2030-10-14 · 4.5y away
MCC
Ph3 Readout
2031-09-26 · 5.5y away
IgAN
TerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03048338 | Approved | IgAN | Not yet recr... | 1631 | PFS |
| NCT07371961 | Approved | IgAN | Not yet recr... | 2467 | EDSS |
| NCT04775382 | Approved | MCC | Terminated | 2866 | ACR20 |
Competitors (10)